Entrada Therapeutics Stock (NASDAQ:TRDA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$17.77

52W Range

$10.75 - $20.49

50D Avg

$16.80

200D Avg

$15.15

Market Cap

$670.94M

Avg Vol (3M)

$138.25K

Beta

-0.27

Div Yield

-

TRDA Company Profile


Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

177

IPO Date

Oct 29, 2021

Website

TRDA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
License$139.00M

Fiscal year ends in Dec 23 | Currency in USD

TRDA Financial Summary


Dec 23Dec 22Dec 21
Revenue$129.01M--
Operating Income$-3.16M$-97.25M$-51.13M
Net Income$-6.68M$-87.46M$-50.07M
EBITDA$-321.00K$-97.25M$-51.13M
Basic EPS$-0.20$-2.79$-7.99
Diluted EPS$-0.20$-2.79$-7.99

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
VIGLVigil Neuroscience, Inc.
PMVPPMV Pharmaceuticals, Inc.
CGEMCullinan Oncology, Inc.
CNTACentessa Pharmaceuticals plc
LRMRLarimar Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
IRONDisc Medicine, Inc.
RLYBRallybio Corporation
TYRATyra Biosciences, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
GLUEMonte Rosa Therapeutics, Inc.
PHVSPharvaris N.V.
GNTAGenenta Science S.p.A.
PEPGPepGen Inc.
THRDThird Harmonic Bio, Inc.
MOLNMolecular Partners AG
PRDSPardes Biosciences, Inc.
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.